Olpasiran (AMG 890)
Elevated Lipoprotein(a) for Cardiovascular Risk Reduction
Phase 3Active
Key Facts
Indication
Elevated Lipoprotein(a) for Cardiovascular Risk Reduction
Phase
Phase 3
Status
Active
Company
About Amgen
Amgen is a foundational pillar of the global biotechnology industry, with a mission to serve patients by transforming the promise of science into therapies that restore health or save lives. The company has achieved a dominant market position through its deep expertise in biologics manufacturing, a diversified portfolio of blockbuster medicines, and a robust pipeline targeting major therapeutic areas including cardiovascular disease, obesity, oncology, and inflammation. Its strategy is centered on leveraging advanced technologies like AI and human genetics to accelerate innovation, expand its manufacturing footprint, and deliver long-term growth.
View full company profileOther Elevated Lipoprotein(a) for Cardiovascular Risk Reduction Drugs
| Drug | Company | Phase |
|---|---|---|
| Zerlasiran (SLN360) | Silence Therapeutics | Phase 2 |